A phase II study, with a safety lead-in, to evaluate ATX-101, a peptide drug targeting PCNA, in advanced dedifferentiated liposarcoma and leiomyosarcoma.

ATX-101 - APIM Therap

Sminu Bose; Matthew Ingham; Shahnaz V. Singh-Kandah; Wendy Magana; Gary K. Schwartz

Apr 28, 2022